Find your future career

Join Grünenthal

experienced professionals

Stronger together:

Take up the challenge

Young Professionals

Come on board:

Kick start your career

Students

Get experience:

Internships for students

Logo Be!Grünenthal

We research, we develop, we bring true innovations to the marketplace. Is that also your goal? Do you also want to sustainably improve the lives of our patients?

Are you an innovative researcher, an unconventional thinker, a strategist, a visionary, a creative thinker, a pragmatist, or a go-getter? In short, are you a person who will rise to the challenge and make a difference?

Then we look forward to telling you more about Grünenthal—about us, what makes us tick, and how we can reach our goals together - every day, worldwide.

Annette, Communications Management, experienced professionals, Grünenthal, wide range of challenges, contribute to the company’s success

Annette, Communications Management

"There’s a wide range of challenges in an inspiring environment here. It’s great to contribute to the company’s success.”

What drives us and what we do - Stay up to date with all the happenings at Grünenthal

Our news


30 Oct 2018

Grünenthal agrees US$ 922 m deal with AstraZeneca for Nexium and Vimovo

Aachen, Germany, 30 October 2018 – Grünenthal today announced that it has agreed to acquire AstraZeneca’s European rights to Nexium and the global (ex US and Japan) rights to Vimovo for a total consideration of up to US$ 922 m (€ 811 m). Nexium (esomeprazole) is a proton pump inhibitor (PPI) that helps to reduce the amount of acid produced by the stomach in patients with gastroesophageal reflux conditions and ulcers. It has a number of indications, including the prevention and treatment of gastric ulcers induced by pain-relieving non-steroidal anti-inflammatory drugs (NSAIDs). Vimovo is a fixed-dose combination tablet of naproxen, a pain-relieving non-steroidal anti-inflammatory drug (NSAID) and esomeprazole, the same gastroprotective active ingredient as in Nexium.

More ...

28 Aug 2018

Duzallo®, a fixed-dose combination therapy for gout, approved in Europe

Aachen, Germany, 28 August 2018 – Today, Grünenthal announced that the European Commission has followed the positive opinion of the Committee for Medicinal Products for Human Use (CHMP) and granted Duzallo® marketing authorization for the EU/EEA. Duzallo® is a fixed-dose combination (FDC) therapy that combines allopurinol and lesinurad. It is indicated for the treatment of hyperuricaemia in adult gout patients who have not been able to reach target levels of uric acid serum with a dose of allopurinol alone. Lesinurad is the first innovative uricosuric in gout treatment for over 40 years.

More ...

previous [2] next [2]

awards